FDA Approved: ATROVENT HFA — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for ATROVENT HFA (ipratropium bromide) filed by Boehringer Ingelheim Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• ATROVENT HFA (IPRATROPIUM BROMIDE)

Snippet

SUPPL AP for ATROVENT HFA (IPRATROPIUM BROMIDE)